Furthermore, AKT2 overexpression was associated with the resistance to erlotinib in pancreatic cancer cell lines [17], indicating that AKT2 is involved in the occurrence of drug resistance. This evidence concerns the gene AKT2 and familial pancreatic carcinoma.